2017 Annual Meeting | C243 - Assessment of Rapidly Progressive Dementias II: Autoimmune Encephalopathies and Infections Presenting as Rapidly Progressive Dementia

Date Friday 04/28/17

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Michael D. Geschwind, MD, PhD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with the differential diagnosis of infectious and non-prion neurodegenerative disease causes of RPD. They should understand the clinical presentation and be able to evaluate for the more common causes of RPD.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
03:30 PM - 03:35 PM	Luncheon	Introduction Michael D. Geschwind, MD, PhD, FAAN
03:35 PM - 04:25 PM	Speaker	Infectious Causes of Rapidly Progressive Dementia Allen J. Aksamit, Jr., MD, FAAN
04:25 PM - 05:15 PM	Speaker	Autoimmune and Antibody-mediated Causes of Rapidly Progressive Dementia Jeffrey M. Gelfand, MD, MAS, FAAN
05:15 PM - 05:30 PM	Q&A	Questions and Answers

Faculty Disclosures
Jeffrey M. Gelfand, MD, MAS, FAAN	Dr. Gelfand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.
Michael D. Geschwind, MD, PhD, FAAN	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Allen J. Aksamit, Jr., MD, FAAN	Dr. Aksamit has nothing to disclose.

��ɫ��

��ɫ��